MEDIZIN

DOC-CHECK LOGIN

Comprehensive Care – difference and common aspects of acute treatment and chronic care

 

From Prof. Dr. Ley Sander, London, UK

 

Berlin (20. September 2008) – Epilepsy is the most common serious neurological disorder with a lifetime prevalence of between two and five percent. Many of those developing epilepsy do so at a young age.  The prevalence of active epilepsy (ie people with ongoing seizures) is up to one percent of the general population. For many people who develop epilepsy, the condition is short lived, but in about one fifth of those who develop epilepsy the condition becomes chronic with little prospect for full seizure remission.

 

Having recurrent epileptic seizures has implications in a number of life domains and these include education, employment, relationships, and leisure. The propensity to recurrent epileptic seizures may curtail someone’s independence and severely impact on quality of life. An acute epilepsy care model may be adequate in treating seizures acutely and may avoid direct medical complications but usually disregards these important aspects of a person’s life. On the other hand, a comprehensive care model provides a holistic approach to the person with the condition.

 

The delivery of comprehensive care involves a multidisciplinary team whilst acute care is usually based on physician only health delivery, focusing mainly on seizure control. This acute approach may well be adequate for those who have a short lived condition. Comprehensive care often involves voluntary agencies and support groups in addition to the multidisciplinary team. The team delivering comprehensive care usually consists of physicians of various disciplines (neurologists, paediatricians, neurophysiologists, neurosurgeons, psychiatrists, and learning disability specialists), epilepsy specialist nurses, therapists (speech, physio, occupational), social workers as well as counsellors. The team has access to full diagnostic facilities and well as to neurosurgical services. Comprehensive care is proactive and will engage in careful planning of a person’s management path. This is in contrast to acute care which is usually reactive and ad hoc. Comprehensive care is better placed to consider, for instance, the feasibility of epilepsy surgery in an individual person and to plan for it. It may also plan ahead for changes in life status of a person (for example, planned pregnancy).  People with well-controlled epilepsy may wish to taper or stop anti-epileptic drug therapy, and this should be the province of comprehensive care. This comprehensive care usually provides full information to the people it serves and will have an open access policy. Comprehensive epilepsy care also involves planned shared care with the primary care provider. There will be a shared-care protocol as well as guidelines for urgent access to the comprehensive care centre.

 

Despite the intuitive feeling that comprehensive care is better than acute care for people with epilepsy, there is no clear evidence to confirm this. Nevertheless, given the opportunity most people with epilepsy would prefer a comprehensive health delivery approach over the option of ad hoc management. A comprehensive approach usually provides continuity of care which is one of the features that people with epilepsy most appreciate in their assessment of health care delivery.

 

This presentation will discuss these issues, comparing and contrasting the acute care delivery approach to a full comprehensive care model for people with epilepsy.

 

Sander_1

 

Slide 1: Scope of epilepsy.

 

 

Sander_2

 

Slide 2: Compehensive care.

 

 

Sander_3

 

Slide 3: Comprehensive epilepsy care.

 

 

Sander_4

 

Slide 4: Comprehensive care better?

 

 

 


 

Source: 8th European Congress on Epiteptology, Satellite Symposium: “Comprehensive Care of Epilepsy in Europe”, Berlin, 20. September 2008 (Medizin und PR Kommunikation).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…